Efficacy of Eribulin in Soft Tissue Sarcomas

Frontiers in Pharmacology

Antonia Digklia¹  Paul Huang²  Robin L. Jones³  Edward Phillips⁴ 

[1] Department of Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland;Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom;Royal Marsden Hospital, Division of Clinical Sciences, Institute of Cancer Research, London, United Kingdom;Royal Marsden Hospital, London, United Kingdom;

关键词: sarcoma;    eribulin and related compounds;    eribulin;    STS;    liposarcoma;    leiomyosarcoma;   

DOI  :  10.3389/fphar.2022.869754

来源: DOAJ

【 摘 要 】

Soft tissue sarcomas are a highly heterogenous group of tumors with limited systemic therapy options. Eribulin, a synthetic analogue of halichondrin B, is a potent mitotic inhibitor. A phase 3 trial of previously treated advanced Liposarcoma and Leiomyosarcoma demonstrated superiority of eribulin to dacarbazine. Eribulin appears to be particularly effective for liposarcomas. It has also been shown to be a safe and effective treatment alternative to doxorubicin in patients where doxorubicin is contraindicated. From retrospective studies, eribulin has demonstrated efficacy in patients with angiosarcoma, pleomorphic sarcomas, synovial sarcomas, rhabdomyosarcomas, angiosarcomas, and myxofibrosarcomas. Future areas of development include liposomal eribulin, which may provide increased efficacy and lower toxicity, and delineation of biomarkers of response and resistance, allowing better selection of patients for treatment.

【 授权许可】

Unknown